In-Vivo Vascular Response Study  
Renu Virmani, M.D., CV Pathology Institute, MD, U.S.A.

Objective and purpose: In-Vivo chronic evaluation of vascular response after stenting using Cobra PzF Coronary Stent System (CeloNova® BioSciences, Inc.) in the Porcine Model (5, 28, and 90 day evaluation)

Design: Pre-clinical Porcine Study (N=66)

Endpoints: Histologic Inflammation Score, Morphologic Neointimal Area, Thrombus formation at 5 days, 28 days, and 90 days

Cobra PzF™ demonstrates lower neointimal response at 28 and 90-days

Acute Swine Shunt Model Study  Renu Virmani, M.D., CV Pathology Institute, MD, U.S.A.

Objective and purpose: Evaluation of Cobra PzF Stents in an acute shunt model. Assess the thrombo-resistance of Cobra PzF compared to leading CoCr BMS

Design: Acute Swine Shunt Model (N=12)

Endpoints: Platelet coverage intensity and platelet positive area

Cobra PzF™ demonstrates reduced platelet adhesion and thrombus formation

LEGEND:  
Leading CoCr BMS  
Cobra PzF™
ATLANTA-FME (France & Middle East)

Interim Analysis of the French experience (n=379) 12-month follow-up
- A retrospective, multicenter review of a prospective database with the CATANIA™ stent in France and the Middle East
- Current interim analysis concentrated on French patients with completed 12-month follow-up
- All patients underwent PCI with CATANIA stent
- There was no exclusion criteria

12-month Clinical Outcomes Compared with Published Data

<table>
<thead>
<tr>
<th>Event</th>
<th>Leading CoCr BMS</th>
<th>PzF Modified Stent</th>
<th>DES</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR</td>
<td>12%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>MACE</td>
<td>7.0%</td>
<td>3.9%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Cardiac Death</td>
<td>0.8%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>MI</td>
<td>2%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Late ST</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Late Stent Thrombosis</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0%</td>
</tr>
</tbody>
</table>